ISRCTN77852934进行中（未招募）2 期
A randomized, controlled trial to determine the efficacy of active topical nail solution versus placebo nail solution for the treatment of pedal onychomycosis
Marlinz Pharma0 个研究点目标入组 70 人开始时间: 2024年7月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female participants aged 18 years or older
- •2. If female is of childbearing potential, she must not be pregnant at the time of enrollment and she must be using an accepted form of birth control during the study treatment period (acceptable forms include: post-menopausal, surgical sterility, complete abstinence, sterilized sexual partner, tubal occlusion, copper-T intrauterine device, levonorgestrel-releasing intrauterine device, medroxyprogesterone injections, etonogestrel implants, combined pills, norelgestromin/ethinyl estradiol transdermal system, intravaginal device, or Cerazette pill; and for males the use of a condom with spermicide or surgical sterility)
- •3. Participant has a diagnosis of onychomycosis diagnosed by means of history, physical examination, and positive (evidence of fungal hyphae) mycological tissue examination by periodic acid-Schiff (PAS) staining
- •4. At least one toenail with distal subungual involvement, localized to any toe, with at least 10% involvement and including up to 100% involvement of the visible nail plate, any nail plate thickness, with the index nail being the most involved per inspection by the on-site investigator and agreed upon by the designated co-investigator study doctor (Hye Kim, DPM), who will inspect specific clinical photographs of the involved nail/s (the photographs will be obtained at each study site using a specified method, as demonstrated to site investigators, so that the clinical features are appropriately demonstrated)
- •5. Participant has an intact protective cutaneous sensation as measured with the Ipswich test for loss of protective sensation (10-gram monofilament)
- •6. Participant has an intact cutaneous barrier, with or without the presence of hyperkeratotic lesions, with or without concomitant tinea pedis or interdigital maceration, or with or without a history of previous skin ulceration, but without active or current pedal ulceration
- •7. Participant must be a satisfactory candidate for the proposed topical antifungal or placebo intervention
- •8. Participant must display the ability to understand and give informed consent to participation, on a voluntary basis, in the research study
排除标准
- •1. Presence of dermatophytoma, defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed
- •2. Use of any systemic antifungal therapeutic agents within 7 months before the baseline visit, or topical antifungal agent on the feet within 1 month preceding the baseline measurement visit
- •3. Candidate with moccasin tinea pedis involving greater than 50% of either plantar surface
- •4. Candidate requires the use of narcotic analgesic or non-steroidal anti-inflammatory drug/s for 48 hours prior to baseline visit or at any follow-up clinical evaluations
- •5. Candidate has an active drug/alcohol dependence or abuse history
- •6. Candidate has a loss of protective pedal sensation or open cutaneous compromise involving the ipsilateral foot
- •7. Candidate has trauma to the nail that resulting in permanent nail plate discoloration or shape
- •8. Candidate displays radiographic evidence of abnormal lytic or proliferative bone lesion in the toe/s of interest, including recent or healing of an acute fracture, if clinical inspection indicates the potential presence of subungual exostosis (radiographs will be obtained and paid for in the course of usual and customary care, outside of participation in this study)
- •9. Candidate has had previous nail matrix ablative surgery, either chemical or cold steel, on any of the involved digits
- •10. Candidate presents systemic or local contraindications to the proposed application of the topical antifungal nail solution or the placebo agent, such as an uncontrolled cardiac, neurological, hepatic, renal, metabolic, or hematological disease or impairment that has been identified
- •11. Candidate suffers from malignant, or bacterial or viral infectious cause/s of nail plate dystrophy
- •12. Candidate shows signs of substantial peripheral circulatory insufficiency
- •13. Candidate is currently participating in another surgical, device, or drug study or has participated in any research study involving an investigational device or drug, or surgical procedure, within the preceding 30 days
- •14. Candidate is allergic to any of the study products
- •15. Candidate is unwilling or unable to comply with the study procedures
- •16. Candidate is affiliated with the investigator or persons working at a study site, or patient who is an employee of the sponsor’s company
- •17. Candidate is institutionalized because of legal or regulatory order
- •18. Candidate is unable to provide informed consent to voluntarily participate in clinical research.
研究者
相似试验
招募中
不适用
HOME FITNESS ProjectJPRN-UMIN000042340Kyoto University School of Public Health100
招募中
2 期
Investigating the effect of melatonin on myocardial tissue when administered before cardiac surgery in adults.myocardial reperfusion injuryoxidative damageinflammationCardiovascular - Coronary heart diseaseCardiovascular - Other cardiovascular diseasesACTRN12621000543886Sir Charles Gairdner Hospital114
尚未招募
不适用
Home-based virtual rehabililtation for people with persistent symptoms after COVID-19 disease (Long COVID-19)ACTRN12621000031864St Vincent's Hospital Sydney32
已完成
不适用
Effect of calcium supplementation on iron status in children aged 6 to 8 years old supplemented with iroISRCTN48567380niversity of Chile (Chile)194
已完成
不适用
Effect of calcium supplementation on iron bioavailability in women aged 35 to 45 years oldISRCTN89888123niversity of Chile (Chile)28